POVEZANOST POLIMORFIZAMA SOD2 I GST GENA SA RIZIKOM ZA NASTANAK I PROGNOZOM PAPILARNOG KARCINOMA BUBREŽNOG PARENHIMA

  • Katarina Đorđević +381648648855
DOI: https://doi.org/10.5937/mp73-35160
Ključne reči: papilarni karcinom bubrežnog parenhima, SOD2, GST, rizik, preživljavanje

Sažetak


Uvod: Smatra se da karcinom bubrežnog parenhima pripada tumorima čijem nastanku, ali i progresiji doprinosi narušena redoks ravnoteža. Mnoge studije fokusirane su na pronalaženje potencijalnih biomarkera rizika, kao i prognostičkih biomarkera za ove tumore, što bi doprinelo ranom otkrivanju i praćenju progresije ovog karcinoma. Među kandidatima su i polimorfizmi gena za enzime  superoksid dizmutazu 2 (SOD2) i glutation S-transferaze (GST).

Cilj: Cilj rada bio je da se ispita uloga polimorfizama gena za SOD2 i pojedinih GST u nastanaku papilarnog karcinoma bubrežnog parenhima (pKBP), kao i njihov  uticaj na preživljavanje obolelih.

Materijal i metode: U studiju je bilo uključeno 39 pacijenata i 336 kontrolnih ispitanika. SOD2 (rs4880), GSTA1 C69T, GSTM1, GSTT1 i GSTP1 (rs1695) polimorfizmi određeni su odgovarajućim PCR metodoma. Nivo 8-hidroksi-2′-deoksiguanozina (8-OHdG) i benzo(a)piren diol epoksid (BPDE)-DNK adukata je određivan ELISA metodom. Uticaj ispitivanih polimorfizama na postoperativnu prognozu ispitivan je na osnovu raspoloživih podataka o preživljavanju.

Rezultati: Nije uočena statistički značajna povezanost SOD2, GSTA1, GSTM1 i GSTT1 genskih varijanti sa rizikom za nsatanak pKBP (p>0,05). Međutim, nosioci GSTP1 varijantnog genotipa imali su značajno veći rizik za nastanak karcinoma u odnosu na nosioce GSTP1 referentnog genotipa (OR = 16,103, 95% IP = 2,036 – 127,398). Nije uočena statistički značajna povezanost varijantnih genotipova sa sadržajem 8-OHdG i BPDE-DNK adukata (p > 0,05). Ispitivani polimorfizmi nisu se pokazali statsistički značajnim prognostičkim faktorima u preživljavanju obolelih iako je uočeno kraće prživljavanje kod nosilaca SOD2 varijantnog i GSTM1 refefrentnog genotipa  (p > 0,05).

Zaključak: Rezultati ove studije pokazali da je GSTP1 varijantni genotip udružen sa povećanim rizikom od nastanka papilarnog karcinoma bubrežnog parenhima. Da bi se u potpunosti razjasnila uloga ispitivanih polimorfizama u nastanku i progresiji karcinoma, nezavisno ili udruženo sa već utvrđenim faktorima rizika, neophodna su dalja istraživanja na većem broju ispitanika.

Reference


  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2018 Nov [cited 2021 Feb 19];68(6):394–424. Available from: https://pubmed.ncbi.nlm.nih.gov/30207593/

  2. Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications [Internet]. Vol. 16, Nature Reviews Urology. Nature Publishing Group; 2019 [cited 2021 Feb 19]. p. 539–52. Available from: https://pubmed.ncbi.nlm.nih.gov/31278395/

  3. Steffens S, Janssen M, Roos FC, Becker F, Schumacher S, Seidel C, et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma - A multicentre study. Eur J Cancer [Internet]. 2012 Oct 1 [cited 2021 Feb 20];48(15):2347–52. Available from: http://dx.doi.org/10.1016/j.ejca.2012.05.002

  4. Xiao Y, Meierhofer D. Glutathione metabolism in renal cell carcinoma progression and implications for therapies. Int J Mol Sci [Internet]. 2019 Aug 1 [cited 2021 Feb 20];20(15):1–20. Available from: /pmc/articles/PMC6696504/

  5. U C, K B, A B, SA B, F B, J C, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol [Internet]. 2019 Jan 1 [cited 2021 Sep 24];75(1):74–84. Available from: https://pubmed.ncbi.nlm.nih.gov/30243799/

  6. Capitanio U, Montorsi F. Renal cancer. In: The Lancet [Internet]. Lancet Publishing Group; 2016 [cited 2021 Mar 5]. p. 894–906. Available from: https://pubmed.ncbi.nlm.nih.gov/26318520/

  7. Board PG, Menon D. Glutathione transferases, regulators of cellular metabolism and physiology. Biochim Biophys Acta - Gen Subj. 2013 May 1;1830(5):3267–88.

  8. Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D, et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics [Internet]. 2005 [cited 2021 Mar 6];15(5):311–9. Available from: https://pubmed.ncbi.nlm.nih.gov/15864132/

  9. JD H, RC S. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology [Internet]. 2000 [cited 2021 Sep 24];61(3):154–66. Available from: https://pubmed.ncbi.nlm.nih.gov/10971201/

  10. RC S, PW J, AA F. Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett [Internet]. 2000 Mar 15 [cited 2021 Sep 19];112–113:357–63. Available from: https://pubmed.ncbi.nlm.nih.gov/10720752/

  11. Mihailovic S, Coric V, Radic T, Radojevic AS, Matic M, Dragicevic D, et al. The Association of Polymorphisms in Nrf2 and Genes Involved in Redox Homeostasis in the Development and Progression of Clear Cell Renal Cell Carcinoma. Oxid Med Cell Longev. 2021;2021.

  12. VM C, TP S, TD P, GM B-J, AR S-R, SM R-S, et al. GSTM1 genotype is an independent prognostic factor in clear cell renal cell carcinoma. Urol Oncol [Internet]. 2017 Jun 1 [cited 2021 Sep 19];35(6):409–17. Available from: https://pubmed.ncbi.nlm.nih.gov/28284893/

  13. Ćorić C, Ćorić V, Plješa-Ercegovac M, Džamić Z. The role of glutathione transferases in renal cell carcinoma. Med Podml. 2016;67(3):42–8.

  14. JR S, B D, JN E, L E, JI E, D G, et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol [Internet]. 2013 [cited 2021 Sep 24];37(10):1469–89. Available from: https://pubmed.ncbi.nlm.nih.gov/24025519/

  15. Coles B, Nowell SA, MacLeod SL, Sweeney C, Lang NP, Kadlubar FF. The role of human glutathione S-transferases (hGSTs) in the detoxification of the food-derived carcinogen metabolite N-acetoxy-PhIP, and the effect of a polymorphism in hGSTA1 on colorectal cancer risk. Mutat Res - Fundam Mol Mech Mutagen. 2001 Oct 1;482(1–2):3–10.

  16. SZ A-R, RA el-Z, WA A, WW A. A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett [Internet]. 1996 Oct 22 [cited 2021 Sep 19];107(2):229–33. Available from: https://pubmed.ncbi.nlm.nih.gov/8947518/

  17. Pljesa-Ercegovac M, Mimic-Oka J, Dragicevic D, Savic-Radojevic A, Opacic M, Pljesa S, et al. Altered antioxidant capacity in human renal cell carcinoma: Role of glutathione associated enzymes. Urol Oncol Semin Orig Investig [Internet]. 2008 Mar 26 [cited 2021 Mar 5];26(2):175–81. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1078143907000294

  18. Coric VM, Simic TP, Pekmezovic TD, Basta-Jovanovic GM, Radojevic ARS, Radojevic-Skodric SM, et al. Combined GSTM1-Null, GSTT1-Active, GSTA1 Low-Activity and GSTP1-Variant Genotype Is Associated with Increased Risk of Clear Cell Renal Cell Carcinoma. PLoS One [Internet]. 2016 Aug 1 [cited 2021 Sep 29];11(8):e0160570. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0160570

  19. Alavanja M, Baron JA, Brownson RC, Buffler PA, DeMarini DM, Djordjevic M V., et al. Tobacco smoke and involuntary smoking. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans [Internet]. International Agency for Research on Cancer; 2004 [cited 2021 Mar 5]. p. 1–1413. Available from: /pmc/articles/PMC4781536/

  20. Atilgan D, Parlaktas BS, Uluocak N, Kolukcu E, Erdemir F, Ozyurt H, et al. The relationship between ALA16VAL single gene polymorphism and renal cell carcinoma. Adv Urol. 2014;2014.

  21. Dasgupta J, Subbaram S, Connor KM, Rodriguez AM, Tirosh O, Beckman JS, et al. Manganese superoxide dismutase protects from TNF-α-induced apoptosis by increasing the steady-state production of H2O2. Antioxidants Redox Signal [Internet]. 2006 Jul [cited 2021 Mar 6];8(7–8):1295–305. Available from: https://pubmed.ncbi.nlm.nih.gov/16910777/

  22. E K, M H, K B, K G, VN K, RJ H, et al. Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile 105Val polymorphism and bladder cancer: a HuGE-GSEC review. Am J Epidemiol [Internet]. 2007 Jun [cited 2021 Sep 29];165(11):1221–30. Available from: https://pubmed.ncbi.nlm.nih.gov/17404387/

  23. De Martino M, Klatte T, Schatzl G, Remzi M, Waldert M, Haitel A, et al. Renal Cell Carcinoma Fuhrman Grade and Histological Subtype Correlate With Complete Polymorphic Deletion of Glutathione S-Transferase M1 Gene. J Urol. 2010 Mar;183(3):878–83.

  24. D R, V S, A H, DH P, LW H, CR W, et al. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis [Internet]. 1997 Jul [cited 2021 Sep 29];18(7):1285–9. Available from: https://pubmed.ncbi.nlm.nih.gov/9230269/

  25. Zhu Y, Horikawa Y, Yang H, Wood CG, Habuchi T, Wu X. BPDE-Induced Lymphocytic Chromosome 3p Deletions May Predict Renal Cell Carcinoma Risk. J Urol [Internet]. 2008 Jun [cited 2021 Sep 19];179(6):2416. Available from: /pmc/articles/PMC2810745/

  26. Miyake H, Hara I, Kamidono S, Eto H. Prognostic significance of oxidative DNA damage evaluated by 8-hydroxy-2′-deoxyguanosine in patients undergoing radical nephrectomy for renal cell carcinoma. Urology [Internet]. 2004 Nov [cited 2021 Mar 6];64(5):1057–61. Available from: https://pubmed.ncbi.nlm.nih.gov/15533518/

  27. A J, U B, T P, M C, M A, Z D, et al. Partial versus radical nephrectomy for pT1a renal cancer in Serbia. J BUON [Internet]. 2016 Nov 1 [cited 2021 Sep 29];21(6):1449–53. Available from: https://europepmc.org/article/med/28039706

  28. Searchfield L, Price SA, Betton G, Jasani B, Riccardi D, Griffiths DFR. Glutathione S-transferases as molecular markers of tumour progression and prognosis in renal cell carcinoma. Histopathology. 2011 Jan;58(2):180–90.

Objavljeno
2022/07/08
Broj časopisa
Vol. 73 Br. 2 (2022): Medicinski podmladak
Rubrika
Originalni naučni članak